STICH
2016
Surgical Treatment for Ischemic Heart Failure — Extension Study (STICHES, 10-year follow-up)
In 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.
Result
Efficacy: All-cause mortalityHR 0.84 (95% CI 0.73-0.97) · P = 0.02
Below 1 favours coronary-artery bypass grafting plus medical therapy, above 1 favours medical therapy alone.
- Absolute difference
- 7.2 points
- NNT
- 14
Absolute difference and NNT are derived from the event rates.
Also reported: At 10 years, CV death and death-or-CV-hospitalisation also reduced.
- Subtopic
- CABG
- Design
- Open-label RCT with extended follow-up
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2026 HFESC 2024 CCSESC 2021 HFESC/EACTS 2018 RevascularisationACC/AHA 2023 CCDACC/AHA 2021 RevascularisationAHA/ACC 2022 HF
- Source
- Velazquez EJ, et al. N Engl J Med. 2016;374(16):1511-1520.doi 10.1056/NEJMoa1602001
Discussion & critique
Original 5-year STICH result was neutral for the primary endpoint; significant survival benefit emerged only with 10-year follow-up, with substantial crossover between arms. Established a durable survival benefit of CABG in ischaemic cardiomyopathy.